全文获取类型
收费全文 | 7519篇 |
免费 | 618篇 |
国内免费 | 119篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 127篇 |
妇产科学 | 102篇 |
基础医学 | 311篇 |
口腔科学 | 39篇 |
临床医学 | 814篇 |
内科学 | 794篇 |
皮肤病学 | 66篇 |
神经病学 | 301篇 |
特种医学 | 135篇 |
外科学 | 541篇 |
综合类 | 992篇 |
预防医学 | 1721篇 |
眼科学 | 71篇 |
药学 | 1613篇 |
8篇 | |
中国医学 | 260篇 |
肿瘤学 | 332篇 |
出版年
2024年 | 18篇 |
2023年 | 165篇 |
2022年 | 388篇 |
2021年 | 495篇 |
2020年 | 491篇 |
2019年 | 385篇 |
2018年 | 359篇 |
2017年 | 363篇 |
2016年 | 385篇 |
2015年 | 343篇 |
2014年 | 822篇 |
2013年 | 690篇 |
2012年 | 540篇 |
2011年 | 559篇 |
2010年 | 450篇 |
2009年 | 365篇 |
2008年 | 270篇 |
2007年 | 256篇 |
2006年 | 200篇 |
2005年 | 122篇 |
2004年 | 114篇 |
2003年 | 109篇 |
2002年 | 64篇 |
2001年 | 47篇 |
2000年 | 46篇 |
1999年 | 31篇 |
1998年 | 16篇 |
1997年 | 23篇 |
1996年 | 16篇 |
1995年 | 13篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 5篇 |
排序方式: 共有8256条查询结果,搜索用时 15 毫秒
31.
卜丽君陈丽周昀箐王翠锦王英燕韩凤王纪文李浩 《中国卫生质量管理》2022,(9):049-51
对1例癫痫性痉挛患儿采用促皮质素静脉给药时发生静脉外渗至局部皮肤坏死的案例进行解析。针对事件发生原因,制定并采取措施:静脉穿刺难度事前评估,优化临床监护,加强相关知识培训,以肌肉注射代替静脉滴注等,避免了此类事件的再次发生,提升了临床合理用药水平,确保了患者安全。 相似文献
32.
《Vaccine》2022,40(48):6947-6955
BackgroundHuman papillomavirus (HPV) infections were the main cause of anogenital cancers and warts. HPV 6/11/16/18 vaccines provide protection against the high-risk types of HPV responsible for 70% of cervical cancers and 90% of genital warts. This randomized, blinded, non-inferiority phase III trial was to determine whether immunogenicity and tolerability would be non-inferior among women after receiving two novel 4- and 9-valent HPV vaccines (4vHPV, HPV 6/11/16/18; 9vHPV, HPV 6/11/16/18/31/33/45/52/58) compared with those receiving Gardasil 4 (4-valent).Methods1680 females between 20 and 45 years were randomized in a 2:1:1 ratio to 20–26, 27–35, or 36–45 y groups. Subjects then equally assigned to receive 4vHPV, 9vHPV or Gardasil 4 (control) vaccine at months 0, 2, and 6. End points included non-inferiority of HPV-6/11/16/18 antibodies for 4vHPV versus control, and 9vHPV versus control and safety. The immunogenicity non-inferiority was pre-defined as the lower bound of 95% confidence interval (CI) of seroconversion rate (SCR) difference > ?10% and the lower bound of 95% CI of geometric mean antibody titer (GMT) ratio > 0.5.ResultsAmong the three vaccine groups, more than 99% of the participants seroconverted to all 4 HPV types. The pre-specified statistical non-inferiority criterion for the immunogenicity hypothesis was met: all the lower bounds of 95% CIs on SCR differences exceeded ?10% for each vaccine HPV type and the corresponding lower bounds of 95% CIs for GMT ratios > 0.5. Across vaccination groups, the most common vaccination reaction were injection-site adverse events (AEs), including pain, swelling, and redness. General and serious AEs were similar in the three groups. There were no deaths.ConclusionsThis study demonstrated that the novel 4- and 9-valent HPV vaccination was highly immunogenic and generally well tolerated, both of which were non-inferior to Gardasil 4 in immunogenicity and safety. 相似文献
33.
34.
值班和交接班制度是诊疗过程连续性的重要保障。若落实不到位,可能发生患者伤害的不良后果。采用案例分析结合问卷调查方式,阐述值班和交接班制度存在问题,包括值班人员不在岗,值班人员资质不符,医院总值班能力不足,交接班记录不完整等。提出针对性改进建议:加强医务人员依法执业培训;严格管理值班医师资质;健全医疗值班体系;规范记录交接班内容等。 相似文献
35.
马旭东 《中国卫生质量管理》2021,(6):046-50
患者安全问题已经成为世界各国医疗质量管理关注的焦点,从国家层面对医疗质量安全不良事件进行统一定义和分类具有重要意义。通过总结世界卫生组织、美国、英国以及我国目前不良事件分类及严重程度分级情况,结合我国相关上报数据,分析存在问题,建议国家及各级卫生行政部门发挥引导推动作用,医疗机构利用现有国家医疗质量安全相关平台,参考借鉴相关分类,开展同质化医疗质量安全管理工作。 相似文献
36.
胡丹谭晶葛颖杰李晓翠 《中国卫生质量管理》2021,(10):055-58
患者安全文化测评有助于评估医疗机构的安全状况。美国医疗健康研究与质量机构(AHRQ)发布的HSOPSC是患者安全文化测评工具的典型代表。2019年,AHRQ根据相关意见和建议修订完成了HSOPSC 2.0版,在保留1.0版优势的基础上精简了维度和条目数量,具有良好的信度和效度,可以作为我国医疗机构患者安全文化测评的有效工具。但由于测量结果的定量特征,建议辅以定性研究对潜在文化价值和更深层次文化假设进行深入分析,同时思考如何将测评结果与干预措施结合起来,以更好地评估干预效果。 相似文献
37.
医学高等院校实验室是培养医学生创新能力的主要场所,其建设和管理水平是高校科研实力、学科建设实力和人才培养能力的综合体现。将精细化管理模式引用到医学实验室安全管理中,为学生提供一个安全保障的实验环境,才能更有利于实验的顺利开展和高校对人才的培养。本文主要对医学实验室安全管理存在的主要问题进行剖析,并基于精细化管理模式下通过对强化安全教育管理、保障人员配备、引进现代化管理办法等方面创新实验室安全管理进行阐述,为医学高等院校实验室现代化建设提供基本保障。 相似文献
38.
IntroductionCyclin-dependent kinase (CDK)4/6 inhibitor is a first-line therapy for metastatic ER+/HER2-breast cancer. However, there are limited data on safety of combined radiotherapy (RT) and CDK4/6 inhibition.MethodsWe conducted a retrospective study of women with metastatic breast cancer who received palliative RT within 14 days of CDK4/6 inhibitor use. The primary endpoint was toxicity per Common Terminology Criteria for Adverse Events v5. Secondary endpoints were pain response and local control based on clinical assessment and imaging.ResultsThirty patients underwent 36 RT courses with palbociclib (n = 34 courses, 94.4%) or abemaciclib (n = 2, 5.6%). RT was delivered before, concurrently or after CDK4/6 inhibitors in 7 (19.4%), 8 (22.2%), and 21 (58.3%) of cases with median 3.5 days from RT to closest CDK4/6 inhibitor administration. Median RT dose was 30Gy (range 8–40.05Gy). Treated sites included brain (n = 5, 11.6%), spine (n = 19, 44.2%), pelvis (n = 9, 20.9%), other bony sites (n = 6, 14.0%) and others (n = 4, 9.3%). No acute grade ≥3 non-hematologic toxicity occurred. No increased hematologic toxicity was attributable to RT with grade 3 hematologic toxicities rates 16.7%, 0%, and 6.7% before, during, and 2 weeks after RT completion. All but one patient (29/30) achieved symptom relief. Local control rates were 94.4%, 91.7% at 6 and 12 months.ConclusionsThe use of RT within 2 weeks of CDK4/6 inhibitors had low acceptable toxicity and high efficacy, suggesting that it is safe for palliation of metastatic breast cancer. 相似文献
39.
《Vaccine》2021,39(20):2736-2745
IntroductionRevaccination with Bacillus Calmette-Guérin (BCG) vaccine is not generally recommended due to a lack of proven efficacy of repeat doses for protection against tuberculosis. However, there is a growing interest in the use of BCG vaccine for its ‘off-target’ effects which might involve revaccination. We did a systematic review of the safety of BCG revaccination.MethodsMEDLINE (1946 to March 2020) and the BCG World Atlas (updated 2017) were searched, limiting to studies of BCG administration by the intradermal or percutaneous route. Adverse events as well as patient and vaccine characteristics were reviewed.ResultsThe search identified 388 articles, of which 24 met the inclusion criteria. These reported 22 studies comprising eight randomised trials, four case-control studies, four observational studies and six case series or reports. Overall, there was evidence for a small increase in the rate of mild local and systemic reactions. No serious adverse events were reported in immunocompetent individuals.ConclusionsEvidence to date suggests that revaccination with BCG vaccine carries minimal risk. Future studies of BCG vaccine for novel applications should report adverse event data stratified by prior BCG vaccination status. 相似文献
40.